Commercial healthcare Professional with 20 years’ experience in the pharmaceutical industry
Experienced leader in both Australian and international pharmaceutical markets.
Strong experience launching mega brands such as Caduet® and Eliquis® and developing turnaround growth strategies for products such as Accupril® and Penthrox® (the ‘Green Whistle’).
Andrew is a UK trained physician with a degree in physiology and a degree in medicine from the University of London.
Andrew has vast experience within the pharmaceutical and medical cannabis industries as a Senior Executive leading the medical team at GW Pharmaceuticals, Chief Medical Officer at Senzer Pharmaceuticals & European Medical Director for Intercept Pharmaceuticals
InhaleRx Ltd.’s long term focus is to develop 1st to market, medically registered and integrated inhaled medical cannabis delivery systems.
Partnering with Camargo, InhaleRx Ltd is currently developing a comprehensive registration package utilising the FDA’s 505 (b)(2) pathway that includes the development of a clinical trial program designed to meet the FDA’s requirements for device registration.
InhaleRx Ltd. is also partnering with EC Pharma Pty Ltd for the clinical trials program, with EC Pharma focusing on the Medical Cannabis C-Liquids for clinical trials.
The first steps in the FDA registration process, the development of the Pre-IND package, is already in progress.
InhaleRx Ltd continues to work closely with medical engineering and design partners to develop and bring to market new and more efficient inhaler device solutions to meet the medical and clinical needs of researchers, doctors and patients.
While there are many companies launching recreational vape products around the world, there is an ongoing unmet need for inhaler devices that meet medical and clinical requirements that will stand up to the high standards required to meet Medical Device Registration requirements demanded by Authorities such as as the FDA and TGA.
InhaleRx Ltd is focused on meeting those requirements and delivering medically registered devices to healthcare professionals and patients, utilising ISO13485, GMP and QA processes.
In 2021 we launched Australia’s 1st Medical Cannabis Inhaler Device in Partnership with EC Pharma Pty Ltd and Cannvalate Pty Ltd. The Medihale™ Inhaler Device fills a critical need for Australian Medical Cannabis Patients; a high bioavailability solution for patients requiring fast onset of action, a common requirement for patients experiencing acute pain or acute anxiety attacks, that is not currently met by current oral ingested delivery methods.
EC Pharma Pty Ltd has developed Proprietary Medical Cannabis “C-Liquids”, specifically for use in our Medihale™ Inhaler Device.
Cannvalate Pty Ltd is partnering with EC Pharma Pty Ltd to provide access to Australia’s largest Medical Cannabis Prescriber Network, delivering over 50% of SAS-B Medical Cannabis Prescriptions in Australia, ensuring the InhaleRx Ltd’s Medihale™ device is accessible to patients across Australia!
InhaleRx Ltd is also in discussions with several companies interested in developing their own C-Liquids for exclusive use on our Medihale™ Pods.
